anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated (except in the case of those CNS-active drugs noted above). Consequently, caution is advised if the concomitant administration of venlafaxine and such drugs is required. (see CONTRAINDICATIONS and WARNINGS).

Serotonergic Drugs: Based on the mechanism of action of venlafaxine hydrochloride and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.John's Wort and methylene blue (see CONTRAINDICATIONS and WARNINGS, Serotonin Syndrome). If concomitant treatment of venlafaxine hydrochloride with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see CONTRAINDICATIONS and WARNINGS, Serotonin Syndrome). The concomitant use of venlafaxine hydrochloride with tryptophan supplements is not recommended (see CONTRAINDICATIONS and WARNINGS, Serotonin Syndrome).

Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan. If concomitant treatment of venlafaxine hydrochloride with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS, Serotonin Syndrome).

Drug-Laboratory Test Interactions

False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.
NEW MATERIAL:An antitumor active substance active to suppress the proliferation of tumor cell and containing a polypeptide of formula I (X is Cys or Ser; Z is H or peptide having the amino acid sequence of formula II or peptide or amino acid following the sequence from its N-terminal and deficient of one or more amino acids) as a constituent protein. USE:Antitumor agent. PREPARATION:An immuno-competent cell originated from mammal, e.g. mononuclear cell such as lymphocyte (e.g. T-cell, B-cell, etc.), monocyte, macrophage, etc., is cultured in a medium normally used in cell culture preferably in the presence of an agent for inducing antitumor substance (e.g. phytohemagglutinin, concanavalin A, etc.). The objective antitumor active substance can be separated from the resultant supernatant liquid of the culture product by conventional method used in the separation of proteinous substance.
The olanzapine kit will consist of two capsules each containing two 2.5 mg tablets of olanzapine (Olanzapine Stada®, STADA Nordic); i.e. total dose 10mg. The capsules will be delivered to the patient with instruction to take the capsule orally along with other standardized pre-procedure medicine. Patient intake will be recorded.
Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes was given over the painful area. GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
PURPOSE: A wrinkle repairing and elasticity improving composition is provided to have alisol- B-23-acetate for enhancing elasticity in skin and promoting fibroblast collagen synthesis for repairing wrinkles and be used in medicine, cosmetic materials or food. CONSTITUTION: A wrinkle repairing and elasticity improving composition comprises a chemical substance represented as chemical formula 1. The chemical composition enhances the elasticity of skin and repairs wrinkles by promoting producing collagen. The chemical substance represented as chemical formula 1 comprises 0.0001-10 parts by weight % of composition. Medicine for external use enhancing skin elasticity and repairing wrinkles comprises a chemical substance represented as chemical formula 1. A cosmetic substance composition for enhancing skin elasticity and repairing wrinkles comprises a chemical substance represented as chemical formula 1. Food supplement for enhancing skin elasticity and repairing wrinkles comprises a chemical substance represented as chemical formula 1.
Mastectomy is a common and painful procedure in dogs. Wound soaker catheters (WSC) are frequently used to reduce postoperative pain, including pain after mastectomy. The objectives of this case series were to describe the use of WSC for owner administration of postoperative local analgesia in dogs with mammary tumors treated surgically, to identify complications associated with WSC and to determine the frequency of bacterial colonization of the catheters. Twelve WSC were placed in 11 dogs during mastectomy surgery, left in place for three days, protected by a dressing and successfully managed by owners at home. No postoperative antibiotics were administered. No complications were identified in any cases. No bacterial growth was identified on bacteriological analysis of the twelve WSC. These results suggest that the use of WSC is a safe alternative for postoperative analgesia administration following mastectomy in dogs. Future studies comparing dogs with or without WSC with a larger number of dogs are needed to further evaluate efficacy and complications.
<P>PROBLEM TO BE SOLVED: To provide a skin care preparation comprising a proteoglycan of a shark cartilage.  <P>SOLUTION: This skin care preparation has higher transparency and a better moist feeling of use than those of a conventional proteolycan derived from cattle. The skin care preparation exhibits ameliorating effects on dermal stains and ephelides and the ameliorating effects on wrinkles and flabbiness. The skin care preparation exhibits the much better ameliorating effects on the dermal stains, ephelides, wrinkles and flabbiness by using a melanin formation inhibitor such as magnesium L-ascorbate phosphate, a crude drug extract having active oxygen scavenging actions such as Eugenia caryophyllata Thunb., Paeonia albiflora Pall. var. trichocarpe Bunge, Geranium thunbergii Sieb. et Zucc., Panax ginseng C.A. Meyer, Leonurus heterophyllus Sweet and Scuttellaria baicalensis Georg. in combination.  <P>COPYRIGHT: (C)2004,JPO
OBJECTIVE: To analyze the clinical effect of urokinase on the prevention of thrombosis in children with primary nephrotic syndrome.
METHODS: A total of 370 children diagnosed with primary nephrotic syndrome (PNS) in the Children's Hospital of Soochow University and Zibo Maternal and Child Health Hospital from January 2018 to December 2022 were selected as the research objects. The patients were divided into a urokinase adjuvant therapy group and non-urokinase adjuvant therapy group according to the application of drugs. The clinical data of the children were collected, including sex, age, drug application, bleeding during treatment, and telephone follow-up, to record whether thromboembolism occurred in the acute stage and remission stage. The clinical pattern of PNS, renal biopsy, histopathological type, and related laboratory indexes before and after treatment were recorded.
RESULTS: A total of 313 patients were treated with urokinase and 57 patients were not. More thrombotic events was observed in non-urokinase group compared to the urokinase group(2 versus 0 episodes, p = 0.02). The thrombotic events observed included one patient had pulmonary embolism combined with right ventricular thrombosis, and another had intracranial venous thrombosis. More minor bleeding events occurred in urokinase group compared to the non-urokinase group(7 versus 1 episodes, p = 1.0). No major bleeding events occurred in either group.
CONCLUSION: The rational prophylactic use of urokinase anticoagulation in children with PNS can prevent the formation of thromboembolism and has good safety.
PURPOSE: An RNA aptamer to E.coli O157:H7 strain is provided to specifically bind to the strain and to prevent food decay. CONSTITUTION: An RNA aptamer which specifically binds to E.coli O157:H7 has a base selected from sequence numbers 1-4. Uracil(U) and cytosine of sequence numbers 1-4 are substituted with fluorine at 2' hydroxyl group. A biosensor for detecting E.coli O157:H7 contains the RNA aptamer. A pharmaceutical composition for preventing or treating food poisoning, hemolytic uremic syndrome or hemolytic anemia contains the composition. A food additive composition contains the RNA aptamer.
PURPOSE: A composition containing sulfur-ingested fly maggot extract for preventing or treating metabolic diseases is provided to reduce blood lipid. CONSTITUTION: A composition for preventing or treating metabolic diseases contains sulfur-ingested fly maggot(Musca domestica L.) extract as an active ingredient. The extract is ethanol. The metabolic diseases are obesity, diabetes, hyperlipidemia, hypercholesterolemia, artery scleroma, or fatty liver. A health functional food for preventing or treating metabolic diseases contains the extract as an active ingredient. A method for preparing the composition contains a step of extracting Musca domestica L.
BACKGROUND: Muscle-invasive bladder carcinoma (MIBC) is a serious and more advanced stage of bladder carcinoma. N6-Methyladenosine (m6A) is a dynamic and reversible modifications that primarily affects RNA stability and alternative splicing. The dysregulation of m6A in MIBC can be potential target for clinical interventions, but there have been limited studies on m6A modifications in MIBC and their associations with post-transcriptional regulatory processes.
METHODS: Paired tumor and adjacent-normal tissues were obtained from three patients with MIBC following radical cystectomy. The additional paired tissues for validation were obtained from patients underwent transurethral resection. Utilizing Nanopore direct-RNA sequencing, we characterized the m6A RNA methylation landscape in MIBC, with a focus on identifying post-transcriptional events potentially affected by changes in m6A sites. This included an examination of differential transcript usage, polyadenylation signal sites, and variations in poly(A) tail length, providing insights into the broader impact of m6A alterations on RNA processing in MIBC.
RESULTS: The prognostic-related m6A genes and m6A-risk model constructed by machine learning enables the stratification of high and low-risk patients with precision. A novel m6A modification site in the 3' untranslated region (3'UTR) of IGLL5 gene were identified, characterized by a lower m6A methylation ratio, elongated poly(A) tails, and a notable bias in transcript usage. Furthermore, we discovered two particular transcripts, VWA1-203 and CEBPB-201. VWA1-203 displayed diminished m6A methylation levels, a truncated 3'UTR, and an elongated poly(A) tail, whereas CEBPB-201 showed opposite trends, highlighting the complex interplay between m6A modifications and RNA processing. Source code was provided on GitHub ( https://github.com/lelelililele/Nanopore-m6A-analysis ).
CONCLUSIONS: The state-of-the-art Nanopore direct-RNA sequencing and machine learning techniques enables comprehensive identification of m6A modification and provided insights into the potential post-transcriptional regulation mechanisms on the development and progression in MIBC.
Background: Tocilizumab and baricitinib have emerged as potential treatments for patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following the findings of the Recovery Group and the results of the COV-BARRIER study. Unfortunately, there is a lack of guidance regarding the use of these agents in high-risk patients, such as those with obesity. Objective: To compare the outcomes of tocilizumab and baricitinib as potential treatments for obese patients infected with SARS-CoV-2. Methods: This was a multi-center retrospective analysis comparing outcomes of obese patients who received the standard of care plus tocilizumab or baricitinib for the treatment of SARS-CoV-2. Included patients had a BMI >30 kg/m2, needed ICU level care, and required non-invasive or invasive ventilatory support. Results: This study included 64 patients who received tocilizumab and 69 patients who received baricitinib. When examining the primary outcome, patients who received tocilizumab had a shorter duration of ventilatory support (10.0 vs 15.0 days, P = .016) than patients who received baricitinib. Our secondary outcome of in-hospital mortality was lower in the tocilizumab group as well (23.4% vs 53.6%, P < .001). Tocilizumab was also associated with a non-significant reduction in new positive blood cultures (13.0% vs 3.1%, P = .056) and new invasive fungal infection (7.3% vs 1.6%, P = .210). Conclusions: This retrospective review showed a reduced duration of ventilatory support in obese patients who received tocilizumab vs baricitinib. In the future, additional studies should be conducted to further examine and confirm these results.
The invention provides an application of a panaxadiol saponins component in the preparation of the drug for treating the Parkinson disease. The main components of the panaxadiol saponins component comprise Rb1, Rb2, Rb3, Rc and Rd. The drug panaxadiol saponins component is an active ingredient placed alone or together with other drugs and used for constituting the drug together with the pharmaceutically acceptable carriers. The drug is prepared by using the roots of Panax, the root of Panax quinquefolium, the stem leaf of Panax, the stem leaf of Panax quinquefolium and the total extract thereof or total saponins and other raw materials, and then performing chromatographic separation through the combined macroporous adsorption resin and octadecyl silane bonded silica gel column chromatography, purifying and the like. The panaxadiol saponins component provided by the invention can improve the motor function of PD patients, supplement the balance among a variety of neurological functions of the brain, fight against the dopaminergic neurons DEGradation of nigra-striatum system and the neurotoxicity of levodopa drugs, treat the neuropsychic disturbance of the PD patients, and maintain the validity of levodopa drugs in a long time. The structural formula of panaxadiol saponins is as shown in the specification.
1. Technical Result Increase in treatment efficiency.          2. Essence A pharmaceutical composition as an active agent comprises a compound of the formula or a pharmaceutically acceptable salt thereof in pharmaceutically effective amount; said composition is useful for reducing the lightening or pigmentation of skin, for inhibiting tyrosinase and treatment of inflammatory diseases.         3. Field of Application Medicine.
Patients receive afatinib PO QD on days 1-28 and necitumumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Atherosclerosis is a progressive inflammatory disease in which macrophage foam cells play a central role in disease pathogenesis. SPA (surfactant protein A) is a lipid-associating protein involved with regulating macrophage function in various inflammatory diseases. However, the role of SPA in atherosclerosis and macrophage foam cell formation has not been investigated.
METHODS: SPA expression was assessed in healthy and atherosclerotic human coronary arteries and the brachiocephalic arteries of wild-type or ApoE-deficient mice fed high-fat diets for 4 weeks. Hypercholesteremic wild-type and SPA-deficient mice fed a high-fat diet for 6 weeks were investigated for atherosclerotic lesions in vivo. In vitro experiments using RAW264.7 macrophages, primary resident peritoneal macrophages extracted from wild-type or SPA-deficient mice, and human monocyte-derived macrophages from the peripheral blood of healthy donors determined the functional effects of SPA in macrophage foam cell formation.
RESULTS: SPA expression was increased in atherosclerotic lesions in humans and ApoE-deficient mice and in response to a proatherosclerotic stimulus in vitro. SPA deficiency reduced the lipid profiles induced by hypercholesterolemia, attenuated atherosclerosis, and reduced the number of lesion-associated macrophage foam cells. In vitro studies revealed that SPA deficiency reduced intracellular cholesterol accumulation and macrophage foam cell formation. Mechanistically, SPA deficiency dramatically downregulated the expression of scavenger receptor CD36 (cluster of differentiation antigen 36) cellular and lesional expression. Importantly, SPA also increased CD36 expression in human monocyte-derived macrophages.
CONCLUSIONS: Our results elucidate that SPA is a novel factor promoting atherosclerosis development. SPA enhances macrophage foam cell formation and atherosclerosis by increasing scavenger receptor CD36 expression, leading to increasing cellular OxLDL influx.
The invention relates to the technical field of virtual reality, in particular to a virtual reality application for comprehensively evaluating the psychological and behavioral behaviors of students. The application comprises a virtual reality environment construction module, wherein diversified situations and scenes are created, and the emotion and cognition of testers are stimulated. The physiological sensing module collects individual physiological index data, objectively measures emotional response and physical state, and provides emotion assessment indexes. The cognitive tasks and measuring module evaluates cognitive functions and attentiveness through the virtual reality interaction tasks and the psychological measuring tool and helps to measure cognitive performance and thinking modes. The self-consciousness measuring module evaluates the level of self-consciousness, self-acceptance and mood-regulating strategies through virtual role play and self-mental communication. The invention can more comprehensively and objectively understand the psychological state and psychological health level of the individual, and is widely applied to the fields of psychological assessment, psychological risk early warning, emotion management and the like.
A multi-level feature fusion classification method for mental disease text comprises the following steps: step one: open dialogue record pretreatment in the process of mental disease inquiry; step two: training a multi-level feature fusion model oriented to the mental disease text; step three: identifying whether the patient has a psychotic disorder or not and a psychotic disorder class. The invention has the technical characteristics and effects that: 1. according to the invention, the TF-IDF algorithm and the CHI algorithm are used for extracting the keywords of the text, so that the dimension of the text classification characteristic is increased. 2. By fusing the keyword features, the local features and the global features, the features which can be used by the classifier are richer, and the accuracy of the classifier is further improved. 3. The convergence speed is faster than other word vector models (e.g., bert, etc.) with smaller volumes. The invention has higher recognition accuracy and recognition speed under the condition of practical application, and can better assist diagnosis.
Blood will be obtained via peripheral venipuncture. The blood will be divided into components (e.g. plasma, serum, microvesicles, and cells) then analyzed. Flow cytometry will be used to determine cell and microvesicle subsets. RNA will be extracted from the various components of blood and will be subjected to gene and microRNA profiling to determine gene expression. DNA will be isolated from the cells to be used in studies investigating epigenetic regulation of genes identified in the screens. Protein will also be isolated from the multiple components to examine the impact of genetic regulation by epigenetic mechanisms or microRNA on protein expression. Peripheral blood mononuclear cells will be placed in tissue culture for study.

Saliva and urine will be obtained the same day as blood for testing.
Disclosed embodiments concern a composition and/or combination, and a method of administering the same as a feed, or to supplement the feed of, aquatic animals, particularly for aquaculture. Disclosed composition and/or combination embodiments may comprise glucan, silica, mineral clay, mannans,  yucca, quillaja , a probiotic, and/or an adhesive agent. The adhesive agent may be selected particularly to facilitate administration to aquatic species. In certain embodiments the adhesive agent comprises an oil, such as soy oil, or a syrup, such as molasses, or combinations thereof. In some embodiments the composition and/or combination may further comprise polyphenol, an antimicrobial, and/or a vaccine. Also disclosed is a method for promoting growth and/or immune function in aquatic animals.
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib represents an effective strategy for treatment of chronic lymphocytic leukemia (CLL), nevertheless about 30% of patients eventually undergo disease progression. Here we investigated by flow cytometry the long-term modulation of the CLL CXCR4dim/CD5bright proliferative fraction (PF), its correlation with therapeutic outcome and emergence of ibrutinib resistance. By longitudinal tracking, the PF, initially suppressed by ibrutinib, reappeared upon early disease progression, without association with lymphocyte count or serum beta-2-microglobulin. Somatic mutations of BTK/PLCG2, detected in 57% of progressing cases, were significantly enriched in PF with a 3-fold greater allele frequency than the non-PF fraction, suggesting a BTK/PLCG2-mutated reservoir resident within the proliferative compartments. PF increase was also present in BTK/PLCG2-unmutated cases at progression, indicating that PF evaluation could represent a marker of CLL progression under ibrutinib. Furthermore, we evidence different transcriptomic profiles of PF at progression in cases with or without BTK/PLCG2 mutations, suggestive of a reactivation of B-cell receptor signaling or the emergence of bypass signaling through MYC and/or Toll-Like-Receptor-9. Clinically, longitudinal monitoring of the CXCR4dim/CD5bright PF by flow cytometry may provide a simple tool helping to intercept CLL progression under ibrutinib therapy.
FIELD: medicine. 
     SUBSTANCE: method involves applying three courses of apitoxitherapy given every other day. One bee sting is given in one session at the first and the third day, two bee stings are given at the fifth and the seventh day, three bee stings are given at the ninth and eleventh day, four bee stings are given at the thirteenth and fifteenth day, five bee stings are given at the seventeenth and nineteenth day at the first treatment course. The second treatment course is given later after 3-4 days long pause. Two bee stings are given at the first and the third day, three bee stings are given at the fifth and the seventh day. Four bee stings are given at the ninth and eleventh day. Five bee stings are given at the thirteenth and fifteenth day. Six bee stings are given at the seventeenth and nineteenth day. The third treatment course is given later after 3-4 days long pause. Three bee stings are given at the first and the third day, four bee stings are given at the fifth and the seventh day. Five bee stings are given at the ninth and eleventh day. Six bee stings are given at the thirteenth and fifteenth day. Seven bee stings are given at the seventeenth and nineteenth day. 
     EFFECT: reduced treatment laboriousness; prevented allergic response occurrence.